retatrutide phase 2 nejm weight loss 48 weeks Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished The MariTide phase 2 trial

Overview of Depression Major depressive disorder (MDD) is a highly prevalent mood disorder characterized by ruminative thoughts, impaired cognition and anhedonia, and attentional control deficits (Marchetti et al., 2012

Cui et al

Orforglipron, an oral small-molecule glp-1 receptor agonist for obesity treatment

Hot Ultrasound Waves Visibly Tightened My Loose Arm Skin Sofwave, a non-invasive high-frequency device, toned my arms when weight lifting couldn't

Your doctor might need to look at adjusting your other medicines, but it is vitally important to only make changes to your medication on the advice of your doctor

Researchers interested in sequential protocols should consult the peptide stacking guide for current evidence on sequential agonist approaches and the peptide cycling guide for washout period recommendations